Mental distress and subsequent use of anxiolytic drugs - A prospective population-based cohort study of 16,000 individuals

Abstract

Aims: To study the relationship between mental distress and later use of anxiolytic drugs, taking into account potential confounders such as lifestyle and socioeconomic factors. Methods: In a prospective cohort study, data from population-based health surveys from three Norwegian counties (2000—01) were linked to data from the Norwegian Prescription Database (NorPD) (2004—07). In the surveys, 9,386 men (43.1% of those invited) and 11,244 women (52.4%) participated. The two age cohorts were 40 and 45 years old (cohort 1) and 60 years old (cohort 2). Participants in each age group were divided into quartiles (Q1—Q4) separately for men and women according to the degree of mental distress, measured by increasing Hopkins Symptom Checklist-10 score (HSCL-10 score) at baseline. Multivariate logistic regression was performed to assess predictors of anxiolytic drug use. Results: At baseline: Increasing HSCL-10 score was associated with: increasing use of specified prescribed drugs, poor health, ever having sought help because of mental distress, musculoskeletal pain, being married or in partnership, low educational level, receiving disability pension and current smoking (except for women 60 years old). Predictors found: There was a graded positive relationship between HSCL-10 score at baseline (2000—01) and the chance of a prescription of anxiolytics during follow-up (2004—07) in the 40 and 45 year olds. Predictors, regardless of age, were: female gender, reported use of hypnotics, having previously sought help because of mental distress and current smoking. Conclusions: HSCL-10 score was related to later use of anxiolytic drugs in a dose response manner.

Keywords

Anxiolytics benzodiazepines HSCL-10 mental distress symptoms pharmacoepidemiology population-based prospective studies

Get full access to this article

View all access options for this article.

References

WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2006. Geneva: WHO ; 2005.

Alonso J. , Angermeyer MC , Bernert S. , Bruffaerts R. , Brugha TS , Bryson H. , et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420:55-64.

The Norwegian Prescription Database. http://www.fhi.no/eway/default.aspx?pid=238&trg=MainArea_5811&MainArea_5811=5903:0:15,4440:1:0:0:::0:0 (accessed 15 March 2008).

NOMESCO Nordic Medico Statistical Committee. Medicines consumption in the Nordic Countries 1999-2003 ; 2004.

Demyttenaere K. , Bonnewyn A. , Bruffaerts R. , De Girolamo G. , Gasquet I. , Kovess V. , et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD) . J Affect Disord 2008; 110(1-2):84-93.

Laurier C. , Dumas J. , Gregoire JP Factors related to benzodiazepine use in Quebec -secondary analysis of survey data. J Pharmacoepidemiol 1992;2(4):73-86.

Kassam A. , Patten SB Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr 2006 ;4:15.

Lagnaoui R. , Depont F. , Fourrier A. , Abouelfath A. , Begaud B. , Verdoux H. , et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004;60(7):523-9.

Hausken AM , Skurtveit S. , Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Safety 2007; 16(8):913-18.

10.

Blennow G. , Romelsjo A. , Leifman H. , Leifman A. , Karlsson G. Sedatives and hypnotics in Stockholm - social factors and kinds of use. Am J Public Health 1994;84(2):242-6.

11.

Hausken AM , Skurtveit S. , Rosvold EO , Bramness JG , Furu K. Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway. Scand J Public Health 2007;35(4):356-64.

12.

Olfson M. , Pincus HA Use of benzodiazepines in the community . Arch Intern Med 1994;154(11):1235-40.

13.

Ohayon MM , Lader MH Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom . J Clin Psychiatry 2002;63(9):817-25.

14.

O’Brien CP Benzodiazepine use, abuse, and dependence . J Clin Psychiatry 2005;66(Suppl 2):28-33.

15.

Strand BH , Dalgard OS , Tambs K. , Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry 2003;57(2):113-18.

16.

Naess O. , Sogaard AJ , Arnesen E. , Beckstrom AC , Bjertness E. , Engeland A. , et al. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol 2008;37(3):481-5.

17.

The Oslo Health Study. Main questionnaire. http://www.fhi.no/dav/66091FDE33734FAB96849B26D9F46333.pdf (accessed 17 January 2006).

18.

Derogatis LR , Lipman RS , Rickels K. , Uhlenhuth EH , Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974;19(1):1-15.

19.

Furu K. , Skurtveit S. , Rosvold E. Drug use questions in Norwegian health surveys - response rate and agreement between specific and open-ended questions. Nor J Epidemiol 2003;13(1):147-54.

20.

Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 2008;18(2):129-36.

21.

Hosmer DW , Lemeshow S. Applied logistic regression, Second edn. New York : Wiley-Interscience; 2000.

22.

Hausken AM , Furu K. , Skurtveit S. , Engeland A. , Bramness JG Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 2009;65(3):295-301.

23.

Mykletun A. , Overland S. , Aaro LE , Liabo HM , Stewart R. Smoking in relation to anxiety and depression: evidence from a large population survey: the HUNT study. European Psychiatry: J Assoc Eur Psychiatrists 2008;23(2):77-84.

24.

Lundesgaard E. , Skurtveit S. , Tverdal A. , Hartz I. Disability pension predict use of anxiolytics and/or hypnotics 20 years later - a prospective study. Pharmacoepidemiol Drug Safety 2008;17:S93.

25.

Sogaard AJ , Selmer R. , Bjertness E. , Thelle D. The Oslo Health Study: the impact of self-selection in a large, population-based survey. Int J Equity Health 2004;3(1):3.

26.

Kleinbaum DG , Morgenstern H. , Kupper LL Selection bias in epidemiologic studies. Am J Epidemiol 1981;113(4):452-63.

27.

Van den Brandt PA , Petri H. , Dorant E. , Goldbohm RA , Van de CS. Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl Sci 1991;13(2):91-6.

28.

National Institute for Health and Clinical Excellence. Management of anxiety (panic disorder with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. London: NICE guidelines; 2004 (amended 2007). http://www.nice.org.uk/Guidance/CG22 (accessed 3 February 2009).

29.

Neutel CI The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005;17(3):189-97.